Fax: (011) 82-2-862-4453
A Phase II study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma
Article first published online: 28 MAR 2002
Copyright © 2002 American Cancer Society
Volume 94, Issue 7, pages 1925–1930, 1 April 2002
How to Cite
Seo, J. H., Whang, Y. M., Kim, B. S., Choi, C. W., Shin, S. W., Kim, Y. H., Kim, J. S. and Goo, B. H. (2002), A Phase II study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma. Cancer, 94: 1925–1930. doi: 10.1002/cncr.10431
- Issue published online: 28 MAR 2002
- Article first published online: 28 MAR 2002
- Manuscript Accepted: 21 NOV 2001
- Manuscript Revised: 25 OCT 2001
- Manuscript Received: 12 JUL 2001
- Brain Korea 21 Project
- anthracycline resistance;
- breast carcinoma;
A Phase II study was performed to investigate the efficacy and tolerability of paclitaxel and ifosfamide chemotherapy for the treatment of anthracycline-resistant metastatic breast carcinoma (MBC).
Recurrent or progressed MBC within 12 months after anthracycline-based chemotherapy was defined as anthracycline-resistant. A 24-hour infusion of paclitaxel (175 mg/m2) on Day 1 and subsequent infusions of ifosfamide (1.8 g/m2/day) with mesna (360 mg/m2/day) on Days 2– 4, were performed every 3 weeks. Twenty-one patients were eligible for toxicity analysis. Response rate and survival duration were evaluated in 21 patients. Frontline chemotherapy was the FAC (5-fluorouracil, doxorubicin, cyclophosphamide) regimen in all patients.
Objective response was found in 9 patients (42.9%), including complete response in 3 (13.4%). Median response duration and median survival duration were 10 months (range, 2–24+) and 19+ months (range, 2–32+), respectively. Sixteen (76%) experienced Grade 3/4 leukopenia controllable with granulocyte macrophage colony-stimulating factor. Other significant toxicities were peripheral neuropathy (n = 3), mucositis (n = 2), and liver dysfunction (n = 1). However, there was no chemotherapy-related death.
Paclitaxel by 24-hour infusion combined with ifosfamide is efficacious in the treatment of anthracycline-resistant MBC with tolerable toxicity. Further trials verifying the result of the authors' study are warranted. Cancer 2002;94:1925–30. © 2002 American Cancer Society.